Andreas Schiermeyer

Dr. Andreas Schiermeyer

Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstr. 6, 52074 Aachen, Germany
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2005 in The Plant Journal
Verified
Journal Article
Closed access
PDF file
CTCorinna Thurow
Corinna Thurow
Andreas SchiermeyerAndreas Schiermeyer
Andreas Schiermeyer
SKStefanie Krawczyk
Stefanie Krawczyk
TBThomas Butterbrodt
Thomas Butterbrodt
KNKaloian Nickolov
Kaloian Nickolov
CGChristiane Gatz
Christiane Gatz

1 August 2013 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SSStefan Schillberg
Stefan Schillberg
NRNicole Raven
Nicole Raven
RFRainer Fischer
Rainer Fischer
RTRichard Twyman
Richard Twyman
Andreas SchiermeyerAndreas Schiermeyer
Andreas Schiermeyer
Plants have been used for more than 20 years to produce recombinant proteins but only recently has the focus shifted away from proof-of-principle studies (i.e. is my protein expressed and is it functional?) to a serious consideration of the requirements for sustainable productivity and the regulatory approval of pharmaceutical products (i.e. is my protein safe, is it efficacious, and does the product and process comply with regulatory guidelines?). In this context, plant tissue and cell suspension cultures are ideal production platforms whose potential has been demonstrated using diverse pharmaceutical proteins. Typically, cell/tissue cultures are grown in containment under defined conditions, allowing process controls to regulate growth and product formation, thus ensuring regulatory compliance. Recombinant proteins can also be secreted to the culture medium, facilitating recovery and subsequent purification because cells contain most of the contaminating proteins and can be removed from the culture broth. Downstream processing costs are therefore lower compared to whole plant systems, balancing the higher costs of the fermentation equipment. In this article, we compare different approaches for the production of valuable proteins in plant cell suspension and tissue cultures, describing the advantages and disadvantages as well as challenges that must be overcome to make this platform commercially viable. We also present novel strategies for system and process optimization, helping to increase yields and scalability.

8 March 2016 in Frontiers in Plant Science
Verified
Journal Article
Open access
MMManoj K. Mandal
Manoj K. Mandal
HAHoutan Ahvari
Houtan Ahvari
SSStefan Schillberg
Stefan Schillberg
Andreas SchiermeyerAndreas Schiermeyer
Andreas Schiermeyer
Although the field of molecular farming has significantly matured over the last years, some obstacles still need to be resolved. A major limiting factor for a broader application of plant hosts for the production of valuable recombinant proteins is the low yield of intact recombinant proteins. These low yields are at least in part due to the action of endogenous plant proteases on the foreign recombinant proteins. This mini review will present the current knowledge of the proteolytic enzymes involved in the degradation of different target proteins and strategies that are applied to suppress undesirable proteolytic activities in order to safeguard recombinant proteins during the production process.

3 July 2012 in Plant Biotechnology Journal
Verified
Journal Article
Open access
PDF file
JKJanina Kirchhoff
Janina Kirchhoff
NRNicole Raven
Nicole Raven
ABAlexander Boes
Alexander Boes
JRJean L. Roberts
Jean L. Roberts
SRSean Russell
Sean Russell
SSStefan Schillberg
Stefan Schillberg
Summary: Plant cell suspension cultures can be used for the production of recombinant pharmaceutical proteins, but their potential is limited by modest production levels that may be unstable over long culture periods, reflecting initial culture heterogeneity and subsequent genetic and epigenetic changes. We used flow sorting to generate highly productive monoclonal cell lines from a heterogeneous population of tobacco BY‐2 cells expressing the human antibody M12 by selecting the co‐expressed fluorescent marker protein DsRed located on the same T‐DNA. Separation yielded ∼35% wells containing single protoplasts and ∼15% wells with monoclonal microcolonies that formed within 2 weeks. Thus, enriching the population of fluorescent cells from initially 24% to 90–96% in the six monoclonal lines resulted in an up to 13‐fold increase in M12 production that remained stable for 10–12 months. This is the first straightforward procedure allowing the generation of monoclonal plant cell suspension cultures by flow sorting, greatly increasing the potential of plant cells as an economical platform for the manufacture of recombinant pharmaceutical proteins.

22 February 2005 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
Andreas SchiermeyerAndreas Schiermeyer
Andreas Schiermeyer
Helga SchinkelHelga Schinkel
Helga Schinkel
SAStefanie Apel
Stefanie Apel
RFRainer Fischer
Rainer Fischer
SSStefan Schillberg
Stefan Schillberg

Verified
Journal Article
Open access
PDF file
JJJulia Jansing
Julia Jansing
Andreas SchiermeyerAndreas Schiermeyer
Andreas Schiermeyer
SSStefan Schillberg
Stefan Schillberg
RFRainer Fischer
Rainer Fischer
LBLuisa Bortesi
Luisa Bortesi
The advent of precise genome-editing tools has revolutionized the way we create new plant varieties. Three groups of tools are now available, classified according to their mechanism of action: Programmable sequence-specific nucleases, base-editing enzymes, and oligonucleotides. The corresponding techniques not only lead to different outcomes, but also have implications for the public acceptance and regulatory approval of genome-edited plants. Despite the high efficiency and precision of the tools, there are still major bottlenecks in the generation of new and improved varieties, including the efficient delivery of the genome-editing reagents, the selection of desired events, and the regeneration of intact plants. In this review, we evaluate current delivery and regeneration methods, discuss their suitability for important crop species, and consider the practical aspects of applying the different genome-editing techniques in agriculture.